NCT05762276View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 Administered IM in Adult Participants

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

March 7, 2023

Primary Completion Date

June 27, 2024

Study Completion Date

June 27, 2024

Conditions
Hypercholesterolemia
Interventions
DRUG

VXX-401

A synthetic PCSK9 peptide-based immunotherapy

BIOLOGICAL

Placebo

Normal saline

Trial Locations (5)

Unknown

Northern Beaches Clinical Research, Brookvale

Sutherland Shire Clinical Research, Miranda

Emeritus Research, Sydney

University of the Sunshine Coast (USC), Morayfield

Emeritus Research, Melbourne

All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

Vaxxinity, Inc.

INDUSTRY

NCT05762276 - A Study to Investigate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 Administered IM in Adult Participants | Biotech Hunter | Biotech Hunter